<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="eds" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">eds</book-part-id>
      <title-group>
        <title>Ehlers-Danlos Syndrome, Classic Type</title>
        <alt-title alt-title-type="alt-title">Synonyms: Ehlers-Danlos Syndrome, Classical Type; EDS, Classic Type. Includes: Ehlers-Danlos Syndrome Type I, Ehlers-Danlos Syndrome Type II</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Malfait</surname>
            <given-names>Fransiska</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>Fransiska.Malfait@ugent.be</email>
          <aff>Center for Medical Genetics<break/>Ghent University Hospital<break/>Ghent, Belgium</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wenstrup</surname>
            <given-names>Richard</given-names>
          </name>
          <degrees>MD</degrees>
          <email>richard.wenstrup@cchmc.org</email>
          <aff>Division of Human Genetics<break/>Cincinnati Children's Hospital Medical Center<break/>Cincinnati, Ohio</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>De Paepe</surname>
            <given-names>Anne</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>Anne.DePaepe@ugent.be</email>
          <aff>Center for Medical Genetics<break/>Ghent University Hospital<break/>Ghent, Belgium</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2007-05-29" date-type="created">
          <day>29</day>
          <month>5</month>
          <year>2007</year>
        </date>
        <date iso-8601-date="2011-08-18" date-type="updated">
          <day>18</day>
          <month>8</month>
          <year>2011</year>
        </date>
        <date iso-8601-date="2010-05-11" date-type="revised">
          <day>11</day>
          <month>5</month>
          <year>2010</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="alzheimer-early" document-type="chapter">Early-Onset Familial Alzheimer Disease</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="eds3" document-type="chapter">Ehlers-Danlos Syndrome, Hypermobility Type</related-object>
      <abstract id="eds.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Ehlers-Danlos syndrome (EDS), classic type is a connective tissue disorder characterized by skin hyperextensibility, abnormal wound healing, and joint hypermobility. It includes two previously designated subtypes (EDS type I and EDS type II) that are now recognized to form a continuum of clinical findings. The skin is smooth, velvety to the touch, and hyperelastic; i.e., it extends easily and snaps back after release (unlike lax, redundant skin, as in cutis laxa). The skin is fragile, as manifested by splitting of the dermis following relatively minor trauma, especially over pressure points (knees, elbows) and areas prone to trauma (shins, forehead, chin). Wound healing is delayed, and stretching of scars after apparently successful primary wound healing is characteristic. Complications of joint hypermobility, such as dislocations of the shoulder, patella, digits, hip, radius, and clavicle, usually resolve spontaneously or are easily managed by the affected individual. Other features include hypotonia with delayed motor development, fatigue and muscle cramps, and easy bruising. Less common findings include mitral and tricuspid valve prolapse, aortic root dilatation, and spontaneous rupture of large arteries.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of EDS, classic type is established by family history and clinical examination. Quantitative and qualitative studies of type V collagen chains are usually not useful in confirming a diagnosis. At least 50% of individuals with classic EDS have an identifiable pathogenic variant in <italic toggle="yes">COL5A1</italic> or <italic toggle="yes">COL5A2</italic>, the genes encoding type V collagen; however, this number may be an underestimate, since no prospective molecular studies of <italic toggle="yes">COL5A1</italic> and <italic toggle="yes">COL5A2</italic> have been performed in a clinically well-defined group.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Children with hypotonia and delayed motor development benefit from physiotherapy. Non-weight-bearing exercise promotes muscle strength and coordination. Anti-inflammatory drugs may alleviate joint pain. Those with hypotonia, joint instability, and chronic pain may need to adapt lifestyles accordingly. Dermal wounds are closed without tension, preferably in two layers. For other wounds, deep stitches are applied generously; cutaneous stitches are left in place twice as long as usual; and the borders of adjacent skin are carefully taped to prevent stretching of the scar. Cardiovascular problems are treated in a standard manner.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Young children with skin fragility can wear pads or bandages over the forehead, knees, and shins to avoid skin tears. Older children can wear soccer pads or ski stockings with shin padding during activities. Ascorbic acid (vitamin C) may reduce bruising.</p>
          <p><italic toggle="yes">Surveillance:</italic> Yearly echocardiogram when aortic dilatation and/or mitral valve prolapse are present.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Acetylsalicylate; sports that strain joints.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>EDS, classic type is inherited in an autosomal dominant manner. It is estimated that approximately 50% of affected individuals have inherited the pathogenic variant from an affected parent, and approximately 50% of affected individuals have a <italic toggle="yes">de novo</italic> pathogenic variant. Each child of an affected individual has a 50% chance of inheriting the pathogenic variant. Prenatal testing for pregnancies at increased risk is possible for families in which the variant has been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="eds.Diagnosis">
        <title>Diagnosis</title>
        <sec id="eds.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The diagnosis of Ehlers-Danlos syndrome (EDS), classic type is established by family history and clinical examination. Diagnostic criteria were developed by a medical advisory group in a conference (sponsored by the Ehlers-Danlos Foundation [USA] and the Ehlers-Danlos Support Group [UK]) at Villefranche in 1997 [<xref ref-type="bibr" rid="eds.REF.beighton.1998">Beighton et al 1998</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291096-8628%2819980428%2977:1%3C31::AID-AJMG8%3E3.0.CO;2-O/pdf">full text</ext-link>; pdf).</p>
          <p>The combination of the first three <bold>major diagnostic criteria</bold> should have a high specificity for EDS, classic type. The presence of one or more <bold>minor criteria</bold> contributes to the diagnosis of EDS, classic type but is not sufficient to establish the diagnosis.</p>
          <p>
            <bold>Major diagnostic criteria for the classic type of EDS</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Skin hyperextensibility.</bold> Skin hyperextensibility (see <xref ref-type="fig" rid="eds.F1">Figure 1</xref>) should be tested at a neutral site (one not subjected to mechanical forces or scarring), such as the volar surface of the forearm. It is measured by pulling up the skin until resistance is felt. In young children, hyperextensibility of the skin is difficult to assess because of abundant subcutaneous fat.</p>
            </list-item>
            <list-item>
              <p><bold>Widened atrophic scars.</bold> (see <xref ref-type="fig" rid="eds.F2">Figure 2</xref>) (a manifestation of tissue fragility)</p>
            </list-item>
            <list-item>
              <p><bold>Joint hypermobility</bold>. Joint hypermobility (see <xref ref-type="fig" rid="eds.F3">Figure 3</xref>) depends on age, gender, and family as well as ethnic backgrounds. Joint hypermobility in classic EDS is general, affecting both large and small joints, and is usually noted when a child starts to walk. It should be assessed using the Beighton scale, the most widely accepted grading system for the objective semi-quantification of joint hypermobility (see <xref ref-type="table" rid="eds.T.beightons_criteria_for_joint_hyper">Table 1</xref>).</p>
            </list-item>
            <list-item>
              <p>Positive family history</p>
            </list-item>
          </list>
          <table-wrap id="eds.T.beightons_criteria_for_joint_hyper" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Beighton's Criteria for Joint Hypermobility</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Joint/Finding</th>
                  <th id="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Negative</th>
                  <th id="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Unilateral</th>
                  <th id="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Bilateral</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Passive dorsiflexion of the 5th finger &#x0003e;90&#x000b0;</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">2</td>
                </tr>
                <tr>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Passive flexion of thumbs to the forearm</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">2</td>
                </tr>
                <tr>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Hyperextension of the elbows beyond 10&#x000b0;</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">2</td>
                </tr>
                <tr>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Hyperextension of the knees beyond 10&#x000b0;</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">2</td>
                </tr>
                <tr>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Forward flexion of the trunk with knees fully extended and palms resting on the floor</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0</td>
                  <td headers="hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_3 hd_h_eds.T.beightons_criteria_for_joint_hyper_1_1_1_4" valign="middle" colspan="2" align="left" rowspan="1">1</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>A total score of &#x02265;5 defines hypermobility.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>
            <bold>Minor diagnostic criteria for the classic type of EDS</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Smooth, velvety skin</p>
            </list-item>
            <list-item>
              <p>Molluscoid pseudotumors: fleshy, heaped-up lesions associated with scars over pressure points such as the elbows and knees</p>
            </list-item>
            <list-item>
              <p>Subcutaneous spheroids: small, cyst-like, hard shot-like nodules, freely moveable in the subcutis over the bony prominences of the legs and arms. They occur in approximately one third of affected individuals, are numerous, and feel like hard grains of rice. X-ray reveals an outer calcified layer with a translucent core. The spheroids represent subcutaneous fat globules that have lost their blood supply, becoming fibrosed and calcified.</p>
            </list-item>
            <list-item>
              <p>Complications of joint hypermobility (e.g., sprains, dislocations/subluxations, pes planus)</p>
            </list-item>
            <list-item>
              <p>Muscle hypotonia, delayed gross motor development</p>
            </list-item>
            <list-item>
              <p>Easy bruising</p>
            </list-item>
            <list-item>
              <p>Manifestations of tissue extensibility and fragility (e.g., hiatal hernia, anal prolapse in childhood, cervical insufficiency)</p>
            </list-item>
            <list-item>
              <p>Surgical complications (postoperative hernias)</p>
            </list-item>
          </list>
        </sec>
        <sec id="eds.Testing">
          <title>Testing</title>
          <p><bold>Electron microscopy of a skin biopsy</bold> in EDS, classic type often suggests disturbed collagen fibrillogenesis. A "cauliflower" deformity of collagen fibrils is characteristic [<xref ref-type="bibr" rid="eds.REF.hausser.1994.394">Hausser &#x00026; Anton-Lamprecht 1994</xref>]. However, these findings are not specific for EDS and thus not diagnostic. Furthermore, ultrastructural changes, usually most pronounced in the central parts of the reticular dermis, may be missed if the skin biopsy is not full thickness.</p>
          <p><bold>Biochemical testing on cultured dermal fibroblasts.</bold> Collagen protein analysis is performed on cultured fibroblasts, derived from a skin biopsy in order to obtain a source of protein for electrophoretic analysis of collagen types I, III, and V. The collagens are labeled and analyzed on SDS-polyacrylamide gel electrophoresis. Abnormal proteins migrate differently on the gel when compared to control samples. Since type V collagen is synthesized by fibroblasts at low levels, alterations in electrophoretic mobility are poorly reproducible, making this an ineffective method for routine diagnostic evaluation. The test, however, helps to exclude other subtypes of EDS (e.g., the vascular, kyphoscoliotic, arthrochalasis, and dermatosparaxis types) in individuals in whom clinical differential diagnosis is difficult. Rarely, an abnormal electrophoretic pattern for type I collagen is detected due to the presence of an arginine-to-cysteine substitution in <italic toggle="yes">COL1A1</italic> coding for the pro&#x003b1;1(I) collagen chain of type I collagen [<xref ref-type="bibr" rid="eds.REF.nuytinck.2000.1398">Nuytinck et al 2000</xref>, <xref ref-type="bibr" rid="eds.REF.malfait.2007.387">Malfait et al 2007</xref>]</p>
          <sec id="eds.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Genes.</bold> In the majority of affected families (&#x02265;50%), the pathogenic variant is identified in the genes encoding type V collagen, <italic toggle="yes">COL5A1</italic> and <italic toggle="yes">COL5A2.</italic> However, since no prospective molecular studies of <italic toggle="yes">COL5A1</italic> and <italic toggle="yes">COL5A2</italic> have been performed in a clinically well-defined patient group, this number may underestimate the real proportion of individuals with classic EDS harboring a pathogenic variant in one of these genes.</p>
            <p><bold>Evidence for locus heterogeneity.</bold> A <italic toggle="yes">COL1A1</italic> pathogenic variant, p.Arg134Cys, was identified in two unrelated children with classic EDS [<xref ref-type="bibr" rid="eds.REF.nuytinck.2000.1398">Nuytinck et al 2000</xref>]. The same substitution was subsequently identified in three unrelated persons with aneurysms and rupture of medium-sized arteries in young adulthood. These people also had thin and hyperextensible skin, easy bruising, and abnormal wound healing [<xref ref-type="bibr" rid="eds.REF.malfait.2007.387">Malfait et al 2007</xref>; Malfait and De Paepe, personal observation]. Mutation of <italic toggle="yes">COL1A1</italic>, however, is not a major cause of classic EDS [<xref ref-type="bibr" rid="eds.REF.malfait.2005.28">Malfait et al 2005</xref>].</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Sequence analysis</bold>. Approximately 50% of individuals with classic EDS have an identifiable pathogenic variant in <italic toggle="yes">COL5A1</italic> or <italic toggle="yes">COL5A2</italic>. <italic toggle="yes">COL5A1</italic> null alleles are detected in approximately 30%-40% of individuals with classic EDS [<xref ref-type="bibr" rid="eds.REF.malfait.2005.28">Malfait et al 2005</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Deletion/duplication analysis.</bold> The usefulness of such testing has not been demonstrated, as no deletions or duplications involving <italic toggle="yes">COL5A1</italic> or <italic toggle="yes">COL5A2</italic> as causative of classic EDS have been reported.</p>
              </list-item>
              <list-item>
                <p><bold><italic toggle="yes">COL5A1</italic> null allele test</bold>. The C<italic toggle="yes">OL5A1</italic> null allele test determines if the individual is heterozygous for one of several <italic toggle="yes">COL5A1</italic> polymorphic exonic markers in gDNA and then establishes at the cDNA level whether both alleles are expressed. If only one of the two <italic toggle="yes">COL5A1</italic> alleles is present in cDNA, it is assumed that the absent allele is null. Since this test examines both gDNA and cDNA, <italic toggle="yes">COL5A1</italic> null allele testing requires cultured skin fibroblasts. It does not identify pathgoenic variants within <italic toggle="yes">COL5A1</italic> [<xref ref-type="bibr" rid="eds.REF.malfait.2005.28">Malfait et al 2005</xref>].</p>
              </list-item>
            </list>
            <table-wrap id="eds.T.summary_of_molecular_genetic_testi" position="anchor" orientation="portrait">
              <label>Table 2. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Ehlers-Danlos Syndrome, Classic Type</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of EDS, Classic Type Attributed to Mutation of This Gene</th>
                    <th id="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Allelic Variants Detected&#x000a0;<sup>2</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">COL5A1</italic>
                    </td>
                    <td headers="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">46%&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Exon and whole-gene deletions/duplications&#x000a0;<sup>6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">COL5A2</italic>
                    </td>
                    <td headers="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">4%&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_eds.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Exon and whole-gene deletions/duplications&#x000a0;<sup>6</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="eds.TF.2.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="eds" object-id="eds.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="eds.TF.2.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="eds.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="eds.TF.2.3">
                  <label>3. </label>
                  <p><xref ref-type="bibr" rid="eds.REF.malfait.2005.28">Malfait et al [2005]</xref>, <xref ref-type="bibr" rid="eds.REF.malfait.2005.17">Malfait &#x00026; De Paepe [2005]</xref></p>
                </fn>
                <fn id="eds.TF.2.4">
                  <label>4. </label>
                  <p>Examples of pathogenic variants detected by sequence analysis include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="eds.TF.2.5">
                  <label>5. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="eds.TF.2.6">
                  <label>6. </label>
                  <p>No deletions or duplications involving <italic toggle="yes">COL5A1</italic> or <italic toggle="yes">COL5A2</italic> have been reported to cause Ehlers-Danlos syndrome, classic type. (Note: By definition, deletion/duplication analysis identifies rearrangements that are not identifiable by sequence analysis of genomic DNA.)</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v21/n1/full/ejhg2012162a.html">Clinical Utility Gene Card</ext-link> [<xref ref-type="bibr" rid="eds.REF.mayer.2013">Mayer et al 2013</xref>] for information on test characteristics including sensitivity and specificity.</p>
          </sec>
        </sec>
        <sec id="eds.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> Molecular genetic testing for classic EDS is complicated by the large number of exons in the coding sequences (66 in <italic toggle="yes">COL5A1</italic> and 52 in <italic toggle="yes">COL5A2</italic>) and the wide distribution of pathogenic variants. When a clinical diagnosis of classic EDS is suspected, we recommend the following evaluations:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Perform sequence analysis</bold> by Sanger sequencing of <italic toggle="yes">COL5A1</italic> and <italic toggle="yes">COL5A2</italic> either on gDNA or cDNA. The authors recommend starting with sequence analysis of <italic toggle="yes">COL5A1</italic> on gDNA, as most individuals with classic EDS harbor a unique pathogenic variant in this gene, leading to the introduction of a premature termination codon and nonsense-mediated decay of mRNA. When no <italic toggle="yes">COL5A1</italic> pathogenic variant is found, sequence analysis of <italic toggle="yes">COL5A2</italic> should be performed.</p>
            </list-item>
            <list-item>
              <p><bold>Perform <italic toggle="yes">COL5A1</italic> null allele test and biochemical testing.</bold> If sequence analysis of both <italic toggle="yes">COL5A1</italic> and <italic toggle="yes">COL5A2</italic> does not identify a causal variant in a person with the phenotype of classic EDS, the authors recommend obtaining a skin biopsy in order to perform a C<italic toggle="yes">OL5A1</italic> null allele test and biochemical testing.</p>
            </list-item>
          </list>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variant in the family.</p>
        </sec>
      </sec>
      <sec id="eds.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="eds.Clinical_Description">
          <title>Clinical Description</title>
          <p>Ehlers-Danlos syndrome (EDS) is a connective tissue disorder characterized by skin hyperextensibility, abnormal wound healing, and joint hypermobility. Previously, two subtypes, EDS type I and EDS type II, differing only in phenotypic severity, were recognized; it is now apparent that they form a continuum of clinical findings.</p>
          <p>
            <bold>Skin</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Cutaneous hyperextensibility is one of the cardinal features of EDS in general and of classic EDS in particular. Skin extends easily and snaps back after release (unlike lax, redundant skin, as in cutis laxa).</p>
            </list-item>
            <list-item>
              <p>The skin is smooth and velvety to the touch.</p>
            </list-item>
            <list-item>
              <p>The skin is fragile, as manifested by splitting of the dermis following relatively minor trauma, especially over pressure points (knees, elbows) and areas prone to trauma (shins, forehead, chin). Skin fragility may cause dehiscence of sutured incisions in skin or mucosa.</p>
            </list-item>
            <list-item>
              <p>Wound healing is delayed, and stretching of scars after apparently successful primary wound healing is characteristic. Scars become wide, with a "cigarette-paper"-like or papyraceous appearance.</p>
            </list-item>
            <list-item>
              <p>Other dermatologic features in classic EDS:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Molluscoid pseudotumors (see <xref ref-type="sec" rid="eds.Clinical_Diagnosis">Clinical Diagnosis</xref>)</p>
                </list-item>
                <list-item>
                  <p>Subcutaneous spheroids (see <xref ref-type="sec" rid="eds.Clinical_Diagnosis">Clinical Diagnosis</xref>)</p>
                </list-item>
                <list-item>
                  <p>Piezogenic papules: small, painful, reversible herniations of underlying adipose tissue globules through the fascia into the dermis, such as on medial and lateral aspects of the feet upon standing</p>
                </list-item>
                <list-item>
                  <p>Elastosis perforans serpiginosa: a rare skin condition of unknown etiology characterized by skin-colored to erythematous keratotic papules, some enlarging outwards in serpiginous or arcuate configurations, leaving slightly atrophic centers</p>
                </list-item>
                <list-item>
                  <p>Acrocyanosis: a painless disorder caused by constriction or narrowing of the small blood vessels in the skin (affecting mainly the hands) in which the affected areas turn blue and become cold and sweaty; localized swelling may also occur</p>
                </list-item>
                <list-item>
                  <p>Chilblains: cold injuries, characterized by a red swollen skin that is tender, hot to the touch, and may itch; can develop in less than two hours in skin exposed to cold</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Tissue fragility.</bold> Manifestations of generalized tissue extensibility and fragility are observed in multiple organs:</p>
          <list list-type="bullet">
            <list-item>
              <p>Cervical insufficiency during pregnancy</p>
            </list-item>
            <list-item>
              <p>Inguinal and umbilical hernia</p>
            </list-item>
            <list-item>
              <p>Hiatal and incisional hernia</p>
            </list-item>
            <list-item>
              <p>Recurrent rectal prolapse in early childhood</p>
            </list-item>
          </list>
          <p>
            <bold>Joints</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Complications of joint hypermobility including dislocations of the shoulder, patella, digits, hip, radius, and clavicle may occur and usually resolve spontaneously or are easily managed by the affected individual. Some individuals with classic EDS may experience chronic joint and limb pain, despite normal skeletal radiographs.</p>
            </list-item>
            <list-item>
              <p>Other problems related to the joint hypermobility are joint instability, foot deformities such as congenital clubfoot or pes planus, temporomandibular joint dysfunction, joint effusions, and osteoarthritis [<xref ref-type="bibr" rid="eds.REF.hagberg.2004.178">Hagberg et al 2004</xref>, <xref ref-type="bibr" rid="eds.REF.de_coster.2005a.298">De Coster et al 2005a</xref>, <xref ref-type="bibr" rid="eds.REF.de_coster.2005b.47">De Coster et al 2005b</xref>].</p>
            </list-item>
          </list>
          <p><bold>Neurologic features.</bold> Primary muscular hypotonia may occur and may cause delayed motor development, problems with ambulation, and mild motor disturbance. Fatigue and muscle cramps are relatively frequent. Rarely, CSF leak has been reported to cause postural hypotension and headache in individuals with classic EDS [<xref ref-type="bibr" rid="eds.REF.schievink.2004.65">Schievink et al 2004</xref>].</p>
          <p><bold>Easy bruising.</bold> Easy bruising is a common finding and manifests as spontaneous ecchymoses, frequently recurring in the same areas and causing a characteristic brownish discoloration of the skin, especially in exposed areas such as shins and knees. There is a tendency toward prolonged bleeding (e.g., following brushing of the teeth) in spite of a normal coagulation status.</p>
          <p>
            <bold>Cardiovascular</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Structural cardiac malformations are uncommon in classic EDS.</p>
            </list-item>
            <list-item>
              <p>Mitral valve prolapse and, less frequently, tricuspid valve prolapse may occur. Stringent criteria should be used for the diagnosis of mitral valve prolapse.</p>
            </list-item>
            <list-item>
              <p>Aortic root dilatation may be more common than previously thought [<xref ref-type="bibr" rid="eds.REF.wenstrup.2002.112">Wenstrup et al 2002</xref>]. A recent retrospective study showed that three out of 50 (6%) individuals with classic EDS had aortic dilatation at their first echocardiogram, which was performed at a median age of 16 years. However, the dilatation tended to be of little clinical consequence and the mitral valve prolapse is rarely severe. Medical or surgical intervention is rarely necessary for either [<xref ref-type="bibr" rid="eds.REF.atzinger.2011.826">Atzinger et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p>Spontaneous rupture of large arteries, along with intracranial aneurysms and arteriovenous fistulae, may occur in the rare individual with a severe form of classic EDS.</p>
            </list-item>
          </list>
          <p><bold>Pregnancy</bold> in a woman with classic EDS bears risk for the newborn as well as for the mother. As a whole, these complications are more frequent than in the normal population; however, it is difficult to quantitate the incidence of each complication in affected individuals because no good studies exist:</p>
          <list list-type="bullet">
            <list-item>
              <p>Premature rupture of the membranes and prematurity can occur when the mother is affected, and also when the fetus is affected, especially in the most severe forms.</p>
            </list-item>
            <list-item>
              <p>Because of hypotonia, breech presentation is more frequent if the baby is affected and may lead to dislocation of the hips or shoulder of the newborn.</p>
            </list-item>
            <list-item>
              <p>In affected women, tearing of the perineal skin by forceps and, after delivery, extension of episiotomy incisions and prolapse of the uterus and/or bladder may occur.</p>
            </list-item>
          </list>
        </sec>
        <sec id="eds.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The number of individuals described with pathogenic variants in <italic toggle="yes">COL5A1</italic> or <italic toggle="yes">COL5A2</italic> is relatively small. Although there can be some variability in severity of the phenotype, no genotype/phenotype correlations have emerged to date. In particular, no difference in severity is noted in individuals with a <italic toggle="yes">COL5A1</italic> null variant as compared to individuals with a structural variant or those in whom no allelic variant can be detected.</p>
          <list list-type="bullet">
            <list-item>
              <p>Pathogenic variants in <italic toggle="yes">COL5A1</italic> that encode the amino-terminal region of the pro&#x003b1;1(V) collagen chain appear to be associated with a phenotype that can differ slightly from the classic EDS phenotype.</p>
            </list-item>
            <list-item>
              <p>A p.Gly530Ser substitution in the amino-terminal propeptide of the &#x003b1;1(V) chain may be disease-modifying when present in the heterozygous state and disease-causing in the homozygous state [<xref ref-type="bibr" rid="eds.REF.giunta.2000.72">Giunta &#x00026; Steinmann 2000</xref>, <xref ref-type="bibr" rid="eds.REF.giunta.2002.284">Giunta et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p>A particular splice site variant with a complex outcome within the amino-terminal region of the pro&#x003b1;1(V) collagen chain was recently shown to result in a classic EDS-like phenotype with only minor cutaneous involvement (absence of the characteristic atrophic scarring) but with severe kyphoscoliosis and retinal detachment [<xref ref-type="bibr" rid="eds.REF.symoens.2011.e20121">Symoens et al 2011</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="eds.Penetrance">
          <title>Penetrance</title>
          <p>Inter- and intrafamilial variability in the severity of the phenotype can be great.</p>
          <p>In some families with a non-functional (i.e., null) <italic toggle="yes">COL5A1</italic> allele, an affected member can have a very mild classic EDS phenotype, while other family members may have a severe phenotype [<xref ref-type="bibr" rid="eds.REF.malfait.2005.17">Malfait &#x00026; De Paepe 2005</xref>].</p>
        </sec>
        <sec id="eds.Anticipation">
          <title>Anticipation</title>
          <p>Anticipation is not observed.</p>
        </sec>
        <sec id="eds.Nomenclature">
          <title>Nomenclature</title>
          <p>As a result of the 1997 Villefranche conference on EDS [<xref ref-type="bibr" rid="eds.REF.beighton.1998">Beighton et al 1998</xref>], the former EDS type I and type II are now reclassified as EDS, classic type.</p>
        </sec>
        <sec id="eds.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of EDS type I has been estimated at 1:20,000 [<xref ref-type="bibr" rid="eds.REF.byers.2001">Byers 2001</xref>]. However, it is likely that some individuals with milder manifestations of the disease, previously classified as EDS type II, do not come to medical attention and thus go undetected.</p>
        </sec>
      </sec>
      <sec id="eds.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No other phenotypes are associated with mutation of <italic toggle="yes">COL5A1</italic> or <italic toggle="yes">COL5A2</italic>.</p>
      </sec>
      <sec id="eds.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Other forms of Ehlers-Danlos syndrome (EDS) should be considered in individuals with easy bruising, joint hypermobility, and/or chronic joint dislocation. The disorders in which clinical findings overlap with the classic type of EDS include the following:</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="eds3" document-type="chapter"><bold>Ehlers-Danlos syndrome, hypermobility type</bold></related-object>
<bold>(EDS type III).</bold> In this form, joint hypermobility is the primary manifestation. The skin is often soft or velvety and may be mildly hyperextensible. Subluxations and dislocations are common; they may occur spontaneously or with minimal trauma and can be acutely painful. Degenerative joint disease is common. Chronic pain, distinct from that associated with acute dislocations or advanced osteoarthritis, is a serious complication of the condition and can be both physically and psychologically disabling. Easy bruising is common, but atrophic scarring is more characteristic of the classic type of EDS. Joint hypermobility is the primary clinical manifestation. Skin abnormalities, such as variable skin hyperextensibility and smooth velvety skin, are found; but the presence of atrophic scars in individuals with joint hypermobility suggests the diagnosis of classic EDS.</p>
        <p>The diagnosis of EDS, hypermobility type is based entirely on clinical evaluation and family history. In most individuals with EDS, hypermobility type, the gene in which mutation is causative is unknown and unmapped [<xref ref-type="bibr" rid="eds.REF.malfait.2006a.502">Malfait et al 2006a</xref>]. Haploinsufficiency of <italic toggle="yes">TNXB</italic> (the gene encoding tenascin X) and heterozygosity for missense variants in <italic toggle="yes">TNXB</italic> have been associated with EDS, hypermobility type in a small subset of affected individuals (see <bold>Tenascin X deficiency</bold>) [<xref ref-type="bibr" rid="eds.REF.zweers.2003.214">Zweers et al 2003</xref>, <xref ref-type="bibr" rid="eds.REF.zweers.2005.330">Zweers et al 2005</xref>]. A single occurrence of a <italic toggle="yes">COL3A1</italic> variant in a family thought to have EDS, hypermobility type has been reported. Inheritance is autosomal dominant.</p>
        <p><bold>Tenascin X deficiency.</bold> Homozygous pathogenic variants in <italic toggle="yes">TNXB</italic> have been identified in individuals with an autosomal recessive EDS phenotype characterized by mild joint hypermobility, skin hyperextensibility, and easy bruising but without atrophic scarring [<xref ref-type="bibr" rid="eds.REF.schalkwijk.2001.1167">Schalkwijk et al 2001</xref>, <xref ref-type="bibr" rid="eds.REF.lindor.2005.75">Lindor &#x00026; Bristow 2005</xref>]. Heterozygotes for the same pathogenic variant, especially females, appear to have an EDS hypermobility phenotype.</p>
        <p><bold>Familial joint hypermobility syndrome,</bold> and other syndromes in which hypermobility is found, share hypermobility of the joints with classic EDS; but the absence of skin hyperextensibility and atrophic scarring excludes the diagnosis of classic EDS.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="eds4" document-type="chapter"><bold>Ehlers-Danlos syndrome, vascular type</bold></related-object>
<bold>(EDS type IV)</bold> is characterized by thin, translucent skin; easy bruising; characteristic facial appearance; and arterial, intestinal, and/or uterine fragility. Affected individuals are at risk for arterial rupture, aneurysm, and/or dissection; gastrointestinal perforation or rupture; and uterine rupture during pregnancy. One fourth of individuals with EDS, vascular type experience a significant medical problem by age 20 years and more than 80% by age 40 years. The median age of death is 48 years.</p>
        <p>The diagnosis of EDS, vascular type is based on clinical findings and confirmed by biochemical and/or molecular genetic testing. Biochemical studies in affected individuals demonstrate abnormal electrophoretic mobility and abnormal efficiency of secretion of type III procollagen by cultured dermal fibroblasts. Molecular genetic testing is used to identify pathogenic variants in <italic toggle="yes">COL3A1</italic>. Inheritance is autosomal dominant.</p>
        <p><bold>Ehlers-Danlos syndrome, progeroid form</bold> is a rare autosomal recessive disorder characterized by progeroid appearance with wrinkled facies, curly and fine hair, scanty eyebrows and eyelashes, and periodontitis, in addition to typical signs of EDS. It is caused by homozygous pathogenic variants in <italic toggle="yes">B4GALT7</italic>, the gene encoding beta-1,4-galactosyltransferase 7.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="eds6" document-type="chapter"><bold>Ehlers-Danlos syndrome, kyphoscoliotic form</bold></related-object> (previously known as EDS type VI) is a generalized connective tissue disorder characterized by kyphoscoliosis, joint laxity, muscle hypotonia, and, in some individuals, fragility of the ocular globe. Intelligence is normal; life span may be normal, but affected individuals are at risk for rupture of medium-sized arteries and respiratory compromise if kyphoscoliosis is severe.</p>
        <p>EDS, kyphoscoliotic form is caused by mutation of <italic toggle="yes">PLOD1,</italic> resulting in deficient activity of the enzyme procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1: lysyl hydroxylase 1). The diagnosis of EDS, kyphoscoliotic form relies on the demonstration of an increased ratio of deoxypyridinoline to pyridinoline crosslinks in urine measured by HPLC, a highly sensitive and specific test. Assay of lysyl hydroxylase enzyme activity in skin fibroblasts and molecular genetic testing of <italic toggle="yes">PLOD1</italic> are possible. Inheritance is autosomal recessive.</p>
        <p><bold>Ehlers-Danlos syndrome, arthrochalasia type</bold> (previously called type VIIA &#x00026; B) is distinguished by congenital bilateral hip dislocation and severe joint hypermobility. Tissue fragility (including atrophic scars) and skin hyperextensibility are usually present; severity ranges from mild to severe. It is caused by mutation of <italic toggle="yes">COL1A1</italic> or <italic toggle="yes">COL1A2</italic> leading to the deletion of exon 6 of the mRNA coding for the &#x003b1;1 chain (EDS VIIA) or the &#x003b1;2 chain (EDS VIIB) of type I collagen, respectively. Inheritance is autosomal dominant.</p>
        <p><bold>Ehlers-Danlos syndrome, dermatosparaxis type</bold> (previously called EDS type VIIC) is characterized by extreme skin fragility, laxity, and a sagging, redundant appearance. Other distinct features are delayed closure of the fontanels, characteristic facies, edema of the eyelids, blue sclerae, umbilical hernia, short fingers, and short stature. The disorder is caused by deficient activity of procollagen-N-proteinase, the enzyme that excises the N-terminal propeptide in procollagen types I, II, and III [<xref ref-type="bibr" rid="eds.REF.malfait.2005.28">Malfait et al 2005</xref>]. Inheritance is autosomal recessive.</p>
        <p><bold>Ehlers-Danlos syndrome, cardiac valvular form</bold> is characterized by joint hypermobility, skin hyperextensibility, and sometimes atrophic scarring, as well as cardiac valvular defects. Total absence of the pro&#x003b1;2(I) chains of type I collagen as a result of homozygous or compound heterozygous pathogenic variants in <italic toggle="yes">COL1A2</italic> is causative [<xref ref-type="bibr" rid="eds.REF.schwarze.2004.917">Schwarze et al 2004</xref>, <xref ref-type="bibr" rid="eds.REF.malfait.2006b.e36">Malfait et al 2006b</xref>]. Inheritance is autosomal recessive.</p>
        <p><bold>Classic-like EDS with propensity for arterial rupture.</bold> One arginine-to-cysteine (Arg-to-Cys) substitution in pro&#x003b1;1(I) chain of type I collagen (p.Arg134Cys) has been identified in a series of individuals with a condition reminiscent of classic EDS that manifests as skin hyperextensibility, easy bruising, atrophic scarring, and joint hypermobility as well as a propensity for arterial rupture in adulthood [<xref ref-type="bibr" rid="eds.REF.nuytinck.2000.1398">Nuytinck et al 2000</xref>, <xref ref-type="bibr" rid="eds.REF.malfait.2007.387">Malfait et al 2007</xref>]. Two other pro&#x003b1;1(I) R-to-C substitutions (p.Arg396Cys and p.Arg915Cys) were also associated with rupture of medium-sized arteries, but affected individuals did not have EDS-like skin features [<xref ref-type="bibr" rid="eds.REF.malfait.2007.387">Malfait et al 2007</xref>]. Furthermore, a pro<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="eds-Image001.jpg" mime-subtype="jpeg"/>1(I)-p.Arg888Cys substitution was reported in a family presenting an EDS/osteogenesis imperfecta overlap phenotype [<xref ref-type="bibr" rid="eds.REF.cabral.2007.396">Cabral et al 2007</xref>], and a pro&#x003b1;1(I)-p.Arg836Cys substitution was shown to be associated with autosomal dominant <related-object link-type="booklink" source-id="gene" document-id="caffey" document-type="chapter">Caffey disease</related-object> [<xref ref-type="bibr" rid="eds.REF.gensure.2005.1250">Gensure et al 2005</xref>].</p>
        <p><bold>Ehlers-Danlos syndrome and periventricular nodular heterotopia.</bold> Pathogenic variants in <italic toggle="yes">FLNA</italic> have been identified in a limited number of individuals with periventricular nodular heterotopia (a neuronal migration disorder characterized by seizures and conglomerates of neural cells around the lateral ventricles of the brain) and features of EDS [<xref ref-type="bibr" rid="eds.REF.g_mezgarre.2006.232">G&#x000f3;mez-Garre et al 2006</xref>]. See <related-object link-type="booklink" source-id="gene" document-id="x-pvh" document-type="chapter">X-Linked Periventricular Heterotopia</related-object>.</p>
        <p><bold>Ehlers-Danlos syndrome spondylocheirodyplastic form</bold> is characterized by hyperextensible thin skin, easy bruising, hypermobility of the small joints with a tendency to contractures, protuberant eyes with bluish sclerae, hands with finely wrinkled palms, atrophy of the thenar muscles, and tapering fingers. Skeletal surveys show platyspondyly with moderate short stature, osteopenia, and widened metaphyses. Mutation of <italic toggle="yes">SLC39A13</italic>, encoding the membrane-bound zinc transporter SLC39A13, is causative [<xref ref-type="bibr" rid="eds.REF.giunta.2008.1290">Giunta et al 2008</xref>]. Inheritance is autosomal recessive.</p>
        <p><bold>The <italic toggle="yes">RIN2</italic>-syndrome</bold> (also known as MACS syndrome) is characterized by severe progressive scoliosis, progressive facial coarsening, gingival hypertrophy, sparse hair, and skin and joint hyperlaxity. It is caused by mutation of <italic toggle="yes">RIN2</italic>, the gene encoding the Ras and Rab interactor 2 that acts as a guanine nucleotide exchange factor (GEF) for the small GTPase Rab5, which is involved in early endocytosis [<xref ref-type="bibr" rid="eds.REF.baselvanagaite.2009.254">Basel-Vanagaite et al 2009</xref>, <xref ref-type="bibr" rid="eds.REF.syx.2010.79">Syx et al 2010</xref>]. Inheritance is autosomal recessive.</p>
        <p><bold>Ehlers-Danlos syndrome musculocontractural type</bold> is characterized by craniofacial dysmorphism, hyperextensible thin skin, atrophic scarring, easy bruising, small joint hypermobility, hands with finely wrinkled palms and tapered fingers, congenital contractures of distal joints, scoliosis, progressive muscle hypotonia, and variable gastrointestinal and genitourinary involvement. The condition is caused by mutation of <italic toggle="yes">CHST14</italic>, encoding dermatan 4 sulfotransferase-1, which is involved in the biosynthesis of dermatan sulfate. Inheritance is autosomal recessive [<xref ref-type="bibr" rid="eds.REF.malfait.2010.1233">Malfait et al 2010</xref>, <xref ref-type="bibr" rid="eds.REF.miyake.2010.966">Miyake et al 2010</xref>].</p>
        <p>Classic EDS shows limited overlap with other connective tissue disorders, including variants of the following; these disorders are differentiated by other distinctive clinical features:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="marfan" document-type="chapter"><bold>Marfan syndrome</bold></related-object><bold>,</bold> caused by mutation of <italic toggle="yes">FBN1</italic>, has a broad continuum of clinical manifestations involving the ocular, skeletal, and cardiovascular systems. Lens dislocation, seen in approximately 60%, is a hallmark feature. Myopia, retinal detachment, glaucoma, and early cataract formation are seen. Bone overgrowth leads to long extremities, pectus deformity (excavatum or carinatum), and joint laxity; scoliosis is common. Cardiovascular manifestations include dilatation of the aorta, a predisposition for aortic tear and rupture, mitral valve prolapse with or without regurgitation, tricuspid valve prolapse, and enlargement of the proximal pulmonary artery. Marfan syndrome is a clinical diagnosis based on family history and the observation of characteristic findings in multiple organ systems. Diagnostic criteria have been established. Inheritance is autosomal dominant.</p>
          </list-item>
          <list-item>
            <p><bold>Occipital horn syndrome (OHS)</bold> (see <related-object link-type="booklink" source-id="gene" document-id="menkes" document-type="chapter"><italic toggle="yes">ATP7A</italic>-Related Copper Transport Disorders</related-object>) is characterized by "occipital horns," distinctive wedge-shaped calcifications at the sites of attachment of the trapezius muscle and the sternocleidomastoid muscle to the occipital bone. Occipital horns may be clinically palpable or observed on skull radiographs. Individuals with OHS also have lax skin and joints, bladder diverticula, inguinal hernias, and vascular tortuosity. There is no particular ease of bruising or fragility of the skin. Serum copper concentration and serum ceruloplasmin concentration are low. Mutation of <italic toggle="yes">ATP7A</italic> is causative. Inheritance is X-linked.</p>
          </list-item>
          <list-item>
            <p>Hyperextensible skin should also be distinguished from that observed in the cutis laxa syndromes and in De Barsy syndrome, in which the redundant skin hangs in loose folds and only returns very slowly to its former position. In these syndromes, the skin is not fragile and wound healing is normal. The cutis laxa syndromes result from the loss or fragmentation of the elastic fiber network. They are variably associated with pulmonary, cardiac, arterial, and gastrointestinal abnormalities. Cutis laxa syndromes comprise autosomal dominant, autosomal recessive, and X-linked forms. The autosomal dominant form is caused by mutation of <italic toggle="yes">ELN</italic>, encoding elastin. Autosomal recessive forms of cutis laxa are associated with mutation of the genes encoding fibulin 4 and fibulin 5 (<italic toggle="yes">FBLN4</italic> and <related-object link-type="booklink" source-id="gene" document-id="fbln5-cutis-laxa" document-type="chapter"><italic toggle="yes">FBLN5</italic></related-object>), and more recently also with mutation of <related-object link-type="booklink" source-id="gene" document-id="cutis-laxa" document-type="chapter"><italic toggle="yes">ATP6V0A2</italic></related-object> and <italic toggle="yes">PYCR1</italic>.</p>
          </list-item>
        </list>
      </sec>
      <sec id="eds.Management">
        <title>Management</title>
        <p>For a detailed review of complications and management, see <xref ref-type="bibr" rid="eds.REF.wenstrup.2004">Wenstrup &#x00026; Hoechstetter [2004]</xref>.</p>
        <sec id="eds.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with Ehlers-Danlos syndrome (EDS), classic type, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Clinical examination of the skin with assessment of skin hyperextensibility, atrophic scars and bruises, and other manifestations of classic EDS</p>
            </list-item>
            <list-item>
              <p>Evaluation of joint mobility with use of the Beighton score</p>
            </list-item>
            <list-item>
              <p>Evaluation for hypotonia and motor development in infants and children</p>
            </list-item>
            <list-item>
              <p>A baseline echocardiogram with aortic diameter measurement for individuals under age ten years</p>
            </list-item>
            <list-item>
              <p>Evaluation of clotting factors if severe easy bruising is present</p>
            </list-item>
          </list>
        </sec>
        <sec id="eds.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>In children with hypotonia and delayed motor development, a physiotherapeutic program is important.</p>
          <p>Non-weight-bearing muscular exercise, such as swimming, is useful to promote muscular development and coordination.</p>
          <p>Individuals with muscle hypotonia and joint instability with chronic pain may have to adjust lifestyle and professional choices accordingly. Emotional support and behavioral and psychological therapy may help in developing acceptance and coping skills.</p>
          <p>Dermal wounds should be closed without tension, preferably in two layers. Deep stitches should be applied generously. Cutaneous stitches should be left in place twice as long as usual and additional fixation of adjacent skin with adhesive tape can help prevent stretching of the scar.</p>
          <p>For recommendations on treatment of joint laxity and dislocations, see <related-object link-type="booklink" source-id="gene" document-id="eds3" document-type="chapter">EDS, Hypermobility Type</related-object>. (Note: Surgical stabilization of joints may lead to disappointing, or only temporary, improvement.)</p>
          <p>Anti-inflammatory drugs may help with joint pain.</p>
          <p>Long-term chronic pain may result in the need for mental health services.</p>
          <p>Cardiovascular problems should be treated in a standard manner.</p>
        </sec>
        <sec id="eds.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>Very young children with pronounced skin fragility can wear protective pads or bandages over the forehead, knees, and shins in order to avoid skin tears. Older children who are active can wear soccer pads or ski stockings with shin padding during activities.</p>
          <p>For recommendations on prevention of primary manifestations of joint laxity and dislocations, see <related-object link-type="booklink" source-id="gene" document-id="eds3" document-type="chapter">EDS, Hypermobility Type</related-object>: Management, Prevention of Primary Manifestations.</p>
          <p>Ascorbic acid (vitamin C) may reduce easy bruising but has no effect on the primary findings of skin hyperextensibility, atrophic scarring, and joint hypermobility. In general, a dose of two grams per day is recommended for adults, with proportionally reduced doses for children; however, there is no limitation.</p>
        </sec>
        <sec id="eds.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>For recommendations on prevention of secondary manifestations of joint laxity and dislocations, see <related-object link-type="booklink" source-id="gene" document-id="eds3" document-type="chapter">EDS, Hypermobility Type</related-object>: Management, Prevention of Secondary Complications.</p>
        </sec>
        <sec id="eds.Surveillance">
          <title>Surveillance</title>
          <p>If no abnormalities are found on echocardiogram in an adult, a follow-up echocardiogram is not necessary. (Because longitudinal data on progression of aortic dilation are not available, specific recommendations for follow-up in individuals with a normal aortic diameter are not available.)</p>
          <p>Yearly echocardiogram is warranted if an abnormality such as aortic dilatation or mitral valve prolapse is present.</p>
        </sec>
        <sec id="eds.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>The following should be avoided:</p>
          <list list-type="bullet">
            <list-item>
              <p>Sports with heavy joint strain (contact sports, fighting sports, football, running)</p>
            </list-item>
            <list-item>
              <p>Acetylsalicylate (aspirin)</p>
            </list-item>
          </list>
        </sec>
        <sec id="eds.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="eds.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes</p>
        </sec>
        <sec id="eds.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Because of the increased risk of skin lacerations, postpartum hemorrhages, and prolapse of the uterus and/or bladder, monitoring of women throughout pregnancy and in the postpartum period is recommended.</p>
          <p>Ascorbic acid (vitamin C) may reduce easy bruising (see <xref ref-type="sec" rid="eds.Prevention_of_Primary_Manifestations">Prevention of Primary Manifestations</xref>). In general, a dose of two grams per day is recommended for adults; however, no strict guidelines exist regarding recommended dose during the third trimester of pregnancy.</p>
          <p>Monitoring of pregnant women for preterm labor is warranted during the third trimester when the risk of premature rupture of the membranes is increased.</p>
        </sec>
        <sec id="eds.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="eds.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="eds.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Ehlers-Danlos syndrome (EDS), classic type is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="eds.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>It is estimated that approximately 50% of affected individuals have inherited the pathogenic variant from an affected parent and approximately 50% of affected individuals have a <italic toggle="yes">de novo</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>The parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant should be evaluated by physical examination of the skin with special attention to delayed wound healing, easy bruising, joint hypermobility or recurrent dislocations, and chronic articular pain. If a pathogenic variant has been identified in the proband, molecular genetic testing is performed in the parents.</p>
            </list-item>
          </list>
          <p>Note: Although approximately 50% of individuals diagnosed with classic EDS have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members.</p>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to sibs of the proband depends on the genetic status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.</p>
            </list-item>
            <list-item>
              <p>Although no instances of germline mosaicism have been reported, it remains a theoretical possibility in a minority of cases.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with classic EDS has a 50% chance of inheriting the pathogenic variant.</p>
          <p>
            <bold>Other family members of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent is affected or has a pathogenic variant, his/her family members are at risk.</p>
            </list-item>
          </list>
        </sec>
        <sec id="eds.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>Prediction of phenotype.</bold> Because of intrafamilial clinical variability, it is not possible to predict the phenotype in family members who have inherited a pathogenic variant.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with an autosomal dominant condition has the pathogenic variant or clinical evidence of the disorder, it is likely that mutation occurred <italic toggle="yes">de novo</italic> in the proband; however, the frequency of parental mosaicism is unknown. Additional explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="eds.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the pathogenic variant has been identified in an affected family member, prenatal diagnosis for pregnancies at increased risk may be available from a clinical laboratory that offers either testing for the gene of interest or custom prenatal testing.</p>
          <p>Requests for prenatal testing for conditions which (like classic EDS) do not affect intellect or life span are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic variant has been identified.</p>
        </sec>
      </sec>
      <sec id="eds.Resources">
        <title>Resources</title>
      </sec>
      <sec id="eds.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p>
          <bold>
            <italic toggle="yes">COL5A1</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold> The <italic toggle="yes">COL5A1</italic> cDNA comprises 66 exons distributed over more than 150 kb of genomic DNA. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="eds" object-id="eds.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold> Several types of pathogenic variants have been identified in both <italic toggle="yes">COL5A1</italic> and <italic toggle="yes">COL5A2</italic>:</p>
        <list list-type="bullet">
          <list-item>
            <p>The most common types of molecular defect lead to haploinsufficiency for <italic toggle="yes">COL5A1</italic> mRNA. In approximately 40% of individuals with classic EDS, nonsense or frameshift variants are responsible for a non-functional <italic toggle="yes">COL5A1</italic> allele [<xref ref-type="bibr" rid="eds.REF.schwarze.2000.1757">Schwarze et al 2000</xref>, <xref ref-type="bibr" rid="eds.REF.wenstrup.2000.1766">Wenstrup et al 2000</xref>, <xref ref-type="bibr" rid="eds.REF.schwarze.2001.989">Schwarze et al 2001</xref>, <xref ref-type="bibr" rid="eds.REF.malfait.2005.28">Malfait et al 2005</xref>]. Nonsense, frameshift, or splice-site variants that introduce a premature termination codon are usually responsible for this non-functional <italic toggle="yes">COL5A1</italic> allele. A variety of mechanisms lead to nonsense-mediated decay of the mutation-bearing mRNA or to failure of the chains to associate. The predicted consequence is synthesis of approximately half the amount of normal type V collagen.</p>
          </list-item>
          <list-item>
            <p>Structural variants in <italic toggle="yes">COL5A1</italic>, which exert a dominant-negative effect, have been demonstrated in approximately ten to 15 individuals with classic EDS. In a small proportion of individuals, a variant affects the structural integrity of type V collagen, resulting in the production of a functionally defective type V collagen protein (dominant-negative variant). These structural variants are most commonly splice-site variants that result in exon skipping [<xref ref-type="bibr" rid="eds.REF.burrows.1998.390">Burrows et al 1998</xref>, <xref ref-type="bibr" rid="eds.REF.malfait.2005.28">Malfait et al 2005</xref>] and a few single nucleotide variants that result in the substitution for glycine in the triple-helical region of the collagen molecule [<xref ref-type="bibr" rid="eds.REF.giunta.2000.72">Giunta &#x00026; Steinmann 2000</xref>, <xref ref-type="bibr" rid="eds.REF.malfait.2005.28">Malfait et al 2005</xref>]. A unique single nucleotide variant in <italic toggle="yes">COL5A1</italic> that changes a highly conserved cysteine residue to a serine in the C-terminal propeptide of the &#x003b1;1(V) collagen chain has also been identified (p.Cys1639Ser) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000093.3">NM_000093.3</ext-link>:c.4916G&#x0003e;C). In contrast to other disorders characterized by mutation of the fibrillar collagen genes, remarkably few pathogenic variants resulting from the substitution of a glycine by a bulkier amino acid have been found.</p>
          </list-item>
          <list-item>
            <p>A p.Gly530Ser (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000093.3">NM_000093.3</ext-link>: c.1588G&#x0003e;A) substitution in the amino-terminal propeptide of the &#x003b1;1(V) chain may be disease-modifying when present in the heterozygous state and disease-causing in the homozygous state [<xref ref-type="bibr" rid="eds.REF.giunta.2000.72">Giunta &#x00026; Steinmann 2000</xref>, <xref ref-type="bibr" rid="eds.REF.giunta.2002.284">Giunta et al 2002</xref>].</p>
          </list-item>
        </list>
        <p><bold>Normal gene product.</bold> Collagen &#x003b1;1 (V) chain (type V collagen chains). Type V collagen is a quantitatively minor fibrillar collagen that is widely distributed in a variety of tissues. It is present mainly as [&#x003b1;1(V)]<sub>2</sub> &#x003b1;2(V) heterotrimers in skin, bone, and tendon. It forms heterotypic fibrils with type I collagen and regulates the diameter of those fibrils, presumably through its very large amino-terminal propeptide. Recent data indicate that type V collagen controls collagen fibril assembly in several tissues [<xref ref-type="bibr" rid="eds.REF.wenstrup.2004.53331">Wenstrup et al 2004</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Missense variants in the triple helical domain of the &#x003b1;1(V) or &#x003b1;2(V) chains are likely to have dominant-negative activity; i.e., the mutant forms can interfere with the utilization of the normal protein derived from the normal allele. Diminished amounts, caused by premature termination of codons in <italic toggle="yes">COL5A1</italic> or mRNA product, may alter normal collagen fibrillogenesis.</p>
        <p>
          <bold>
            <italic toggle="yes">COL5A2</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold> The <italic toggle="yes">COL5A2</italic> cDNA comprises 51 exons distributed over 67 kb. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="eds" object-id="eds.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold> Structural pathogenic variants in <italic toggle="yes">COL5A2</italic> have been demonstrated in few individuals with classic EDS. These structural variants are most commonly splice-site variants that result in exon skipping [<xref ref-type="bibr" rid="eds.REF.michalickova.1998.249">Michalickova et al 1998</xref>, <xref ref-type="bibr" rid="eds.REF.malfait.2005.28">Malfait et al 2005</xref>] and one single nucleotide variant that results in a substitution for glycine in the triple helical region of the collagen molecule [<xref ref-type="bibr" rid="eds.REF.richards.1998.846">Richards et al 1998</xref>].</p>
        <p><bold>Normal gene product.</bold> Collagen &#x003b1;2(V) chains (type V collagen chains). Type V collagen is a quantitatively minor fibrillar collagen that is widely distributed in a variety of tissues. It is present mainly as [&#x003b1;1(V)]<sub>2</sub>, &#x003b1;2(V) heterotrimers in skin, bone, and tendon. It forms heterotypic fibrils with type I collagen and regulates the diameter of those fibrils, presumably through its very large amino-terminal propeptide.</p>
        <p><bold>Abnormal gene product.</bold> Missense variants in the triple helical domain of the &#x003b1;1(V) or &#x003b1;2(V) chains are likely to have dominant-negative activity; that is, the mutant forms can interfere with the utilization of the normal protein derived from the normal allele.</p>
      </sec>
      <sec id="eds.References">
        <title>References</title>
        <sec id="eds.Published_GuidelinesConsensus_Statem">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="eds.Published_GuidelinesConsensus_Statem.reflist0">
            <ref id="eds.REF.beighton.1998">
              <mixed-citation publication-type="webpage">Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291096-8628%2819980428%2977:1%3C31::AID-AJMG8%3E3.0.CO;2-O/pdf">online</ext-link>. 1998. Accessed 9-16-15.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="eds.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="eds.Literature_Cited.reflist0">
            <ref id="eds.REF.atzinger.2011.826">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Atzinger</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khoury</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tinkle</surname>
                    <given-names>BT</given-names>
                  </name>
                </person-group>
                <article-title>Cross-sectional and longitudinal assessment of aortic root dilation and valvular anomalies in hypermobile and classic Ehlers-Danlos syndrome.</article-title>
                <source>J Pediatr.</source>
                <year>2011</year>
                <volume>158</volume>
                <fpage>826</fpage>
                <lpage>830.e1</lpage>
                <pub-id pub-id-type="pmid">21193204</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.baselvanagaite.2009.254">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Basel-Vanagaite</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarig</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hershkovitz</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuchs-Telem</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rapaport</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shirazi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shohat</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enk</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birk</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohlhase</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matysiak-Scholze</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maya</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knopf</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peffekoven</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hennies</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horowitz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishida-Yamamoto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sprecher</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>RIN2 deficiency results in macrocephaly, alopecia, cutis laxa, and scoliosis: MACS syndrome.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>85</volume>
                <fpage>254</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">19631308</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.beighton.1998.31">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beighton</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsipouras</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wenstrup</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers- Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK).</article-title>
                <source>Am J Med Genet</source>
                <volume>77</volume>
                <fpage>31</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9557891</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.burrows.1998.390">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burrows</surname>
                    <given-names>NP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholls</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luccarini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harrison</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yates</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pope</surname>
                    <given-names>FM</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>A point mutation in an intronic branch site results in aberrant splicing of COL5A1 and in Ehlers-Danlos syndrome type II in two British families.</article-title>
                <source>Am J Hum Genet</source>
                <volume>63</volume>
                <fpage>390</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9683580</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.byers.2001">
              <mixed-citation publication-type="book">Byers PH. Disorders of collagen biosynthesis and structure. In: Scriver, Beaudet, Sly, Valle, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease</italic>. 2 ed. Edinburgh, UK: Churchill Livingstone; 2001:1065-81.</mixed-citation>
            </ref>
            <ref id="eds.REF.cabral.2007.396">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cabral</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makareeva</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Letocha</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scribanu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fertala</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steplewski</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keene</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Persikov</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leikin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marini</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Y-position cysteine substitution in type I collagen (alpha1(I) R888C/p.R1066C) is associated with osteogenesis imperfecta/Ehlers-Danlos syndrome phenotype.</article-title>
                <source>Hum Mutat.</source>
                <volume>28</volume>
                <fpage>396</fpage>
                <lpage>405</lpage>
                <pub-id pub-id-type="pmid">17206620</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.de_coster.2005a.298">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Coster</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martens</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005a</year>
                <article-title>Oral health in prevalent types of Ehlers-Danlos syndromes.</article-title>
                <source>J Oral Pathol Med</source>
                <volume>34</volume>
                <fpage>298</fpage>
                <lpage>307</lpage>
                <pub-id pub-id-type="pmid">15817074</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.de_coster.2005b.47">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Coster</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van den Berghe</surname>
                    <given-names>LI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martens</surname>
                    <given-names>LC</given-names>
                  </name>
                </person-group>
                <year>2005b</year>
                <article-title>Generalized joint hypermobility and temporomandibular disorders: inherited connective tissue disease as a model with maximum expression.</article-title>
                <source>J Orofac Pain</source>
                <volume>19</volume>
                <fpage>47</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">15779539</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.gensure.2005.1250">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gensure</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e4;kitie</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barclay</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Depalma</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bastepe</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abuzahra</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Couper</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mundlos</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sillence</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ala Kokko</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seidman</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>J&#x000fc;ppner</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders.</article-title>
                <source>J Clin Invest.</source>
                <volume>115</volume>
                <fpage>1250</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15864348</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.giunta.2008.1290">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Giunta</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El&#x000e7;ioglu</surname>
                    <given-names>NH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Albrecht</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eich</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chambaz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janecke</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yeowell</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eyre</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kraenzlin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinmann</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Spondylocheiro dysplastic form of the Ehlers-Danlos syndrome--an autosomal-recessive entity caused by mutations in the zinc transporter gene SLC39A13.</article-title>
                <source>Am J Hum Genet</source>
                <volume>82</volume>
                <fpage>1290</fpage>
                <lpage>305</lpage>
                <pub-id pub-id-type="pmid">18513683</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.giunta.2002.284">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Giunta</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nuytinck</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raghunath</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hausser</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinmann</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Homozygous Gly530Ser substitution in COL5A1 causes mild classical Ehlers-Danlos syndrome.</article-title>
                <source>Am J Med Genet</source>
                <volume>109</volume>
                <fpage>284</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">11992482</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.giunta.2000.72">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Giunta</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinmann</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Compound heterozygosity for a disease-causing G1489E [correction of G1489D] and disease-modifying G530S substitution in COL5A1 of a patient with the classical type of Ehlers-Danlos syndrome: an explanation of intrafamilial variability?</article-title>
                <source>Am J Med Genet</source>
                <volume>90</volume>
                <fpage>72</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10602121</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.g_mezgarre.2006.232">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Garre</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seijo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guti&#x000e9;rrez-Delicado</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castro del R&#x000ed;o</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de la Torre</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Abad</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morales-Corraliza</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puig</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serratosa</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Ehlers-Danlos syndrome and periventricular nodular heterotopia in a Spanish family with a single FLNA mutation.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>232</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15994863</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.hagberg.2004.178">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hagberg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berglund</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korpe</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andersson-Norinder</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Ehlers-Danlos Syndrome (EDS) focusing on oral symptoms: a questionnaire study.</article-title>
                <source>Orthod Craniofac Res</source>
                <volume>7</volume>
                <fpage>178</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">15359504</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.hausser.1994.394">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hausser</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anton-Lamprecht</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Differential ultrastructural aberrations of collagen fibrils in Ehlers-Danlos syndrome types I-IV as a means of diagnostics and classification.</article-title>
                <source>Hum Genet</source>
                <volume>93</volume>
                <fpage>394</fpage>
                <lpage>407</lpage>
                <pub-id pub-id-type="pmid">8168810</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.lindor.2005.75">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lindor</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bristow</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Tenascin-X deficiency in autosomal recessive Ehlers-Danlos syndrome.</article-title>
                <source>Am J Med Genet A</source>
                <volume>135</volume>
                <fpage>75</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">15793839</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.malfait.2005.28">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Malfait</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coucke</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Symoens</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loeys</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nuytinck</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>The molecular basis of classic Ehlers-Danlos syndrome: a comprehensive study of biochemical and molecular findings in 48 unrelated patients.</article-title>
                <source>Hum Mutat</source>
                <volume>25</volume>
                <fpage>28</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">15580559</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.malfait.2005.17">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Malfait</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Molecular genetics in classic Ehlers-Danlos syndrome.</article-title>
                <source>Am J Med Genet C Semin Med Genet.</source>
                <volume>139C</volume>
                <fpage>17</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">16278879</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.malfait.2006a.502">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Malfait</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hakim</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grahame</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2006a</year>
                <article-title>The genetic basis of joint hypermobility syndromes.</article-title>
                <source>Rheumatology</source>
                <volume>45</volume>
                <fpage>502</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16418200</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.malfait.2006b.e36">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Malfait</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Symoens</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coucke</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nunes</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Almeida</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006b</year>
                <article-title>Total absence of the alpha2(I) chain of collagen type I is a rare cause of Ehlers-Danlos Syndrome hyermobility type.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>e36</fpage>
                <pub-id pub-id-type="pmid">16816023</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.malfait.2007.387">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Malfait</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Symoens</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Backer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermanns-L&#x000ea;</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakalihasan</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lapi&#x000e8;re</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coucke</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood.</article-title>
                <source>Hum Mutat</source>
                <volume>28</volume>
                <fpage>387</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">17211858</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.malfait.2010.1233">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Malfait</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Syx</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vlummens</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Symoens</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nampoothiri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermanns-L&#x000ea;</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Laer</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Musculocontractural Ehlers-Danlos Syndrome (former EDS type VIB) and adducted thumb clubfoot syndrome (ATCS) represent a single clinical entity caused by mutations in the dermatan-4-sulfotransferase 1 encoding CHST14 gene.</article-title>
                <source>Hum Mutat</source>
                <volume>31</volume>
                <fpage>1233</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20842734</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.mayer.2013">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mayer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kennerknecht</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinmann</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for: Ehlers-Danlos syndrome types I-VII and variants - update 2012.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2013</year>
                <volume>21</volume>
                <issue>1</issue>
                <pub-id pub-id-type="pmid">22892533</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.michalickova.1998.249">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Michalickova</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Susic</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willing</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wenstrup</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>WG</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Mutations of the alpha2(V) chain of type V collagen impair matrix assembly and produce Ehlers-Danlos syndrome type I.</article-title>
                <source>Hum Mol Genet</source>
                <volume>7</volume>
                <fpage>249</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">9425231</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.miyake.2010.966">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miyake</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kosho</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizumoto</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furuichi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hatamochi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagashima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arai</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawamura</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wakui</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasui</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishida</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohashi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimura</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiina</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saitsu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsurusaki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukushima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikegawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugahara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsumoto</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Loss-of-function mutations of CHST14 in a new type of Ehlers-Danlos syndrome.</article-title>
                <source>Hum Mutat</source>
                <volume>31</volume>
                <fpage>966</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">20533528</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.nuytinck.2000.1398">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nuytinck</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freund</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lagae</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierard</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermanns-Le</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Classical Ehlers-Danlos syndrome caused by a mutation in type I collagen.</article-title>
                <source>Am J Hum Genet</source>
                <volume>66</volume>
                <fpage>1398</fpage>
                <lpage>402</lpage>
                <pub-id pub-id-type="pmid">10739762</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.richards.1998.846">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholls</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harrison</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pope</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burrows</surname>
                    <given-names>NP</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>A single base mutation in COL5A2 causes Ehlers-Danlos syndrome type II.</article-title>
                <source>J Med Genet</source>
                <volume>35</volume>
                <fpage>846</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9783710</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.schalkwijk.2001.1167">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schalkwijk</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zweers</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steijlen</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dean</surname>
                    <given-names>WB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Vlijmen</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Haren</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bristow</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency.</article-title>
                <source>N Engl J Med</source>
                <volume>345</volume>
                <fpage>1167</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">11642233</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.schievink.2004.65">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schievink</surname>
                    <given-names>WI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordon</surname>
                    <given-names>OK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tourje</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Connective tissue disorders with spontaneous spinal cerebrospinal fluid leaks and intracranial hypotension: a prospective study.</article-title>
                <source>Neurosurgery</source>
                <volume>54</volume>
                <fpage>65</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">14683542</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.schwarze.2000.1757">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schwarze</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atkinson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffman</surname>
                    <given-names>GG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenspan</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byers</surname>
                    <given-names>PH</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Null alleles of the COL5A1 gene of type V collagen are a cause of the classical forms of Ehlers-Danlos syndrome (types I and II).</article-title>
                <source>Am J Hum Genet</source>
                <volume>66</volume>
                <fpage>1757</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">10796876</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.schwarze.2004.917">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schwarze</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hata</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKusick</surname>
                    <given-names>VA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shinkai</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoyme</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pyeritz</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byers</surname>
                    <given-names>PH</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Rare autosomal recessive cardiac valvular form of Ehlers-Danlos syndrome results from mutations in the COL1A2 gene that activate the nonsense-mediated RNA decay pathway.</article-title>
                <source>Am J Hum Genet</source>
                <volume>74</volume>
                <fpage>917</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">15077201</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.schwarze.2001.989">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schwarze</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schievink</surname>
                    <given-names>WI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petty</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaff</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Babovic-Vuksanovic</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cherry</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pepin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byers</surname>
                    <given-names>PH</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Haploinsufficiency for one COL3A1 allele of type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV.</article-title>
                <source>Am J Hum Genet</source>
                <volume>69</volume>
                <fpage>989</fpage>
                <lpage>1001</lpage>
                <pub-id pub-id-type="pmid">11577371</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.symoens.2011.e20121">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Symoens</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malfait</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vlummens</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermanns-L&#x000ea;</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Syx</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <article-title>A novel splice variant in the N-propeptide of COL5A1 causes an EDS phenotype with severe kyphoscoliosis and eye involvement.</article-title>
                <source>PLoS One.</source>
                <year>2011</year>
                <volume>6</volume>
                <fpage>e20121</fpage>
                <pub-id pub-id-type="pmid">21611149</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.syx.2010.79">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Syx</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malfait</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Laer</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hellemans</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermanns-L&#x000ea;</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willaert</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benmansour</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verloes</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <article-title>The RIN2 syndrome: a new autosomal recessive connective tissue disorder caused by deficiency of Ras and Rab interactor 2 (RIN2).</article-title>
                <source>Hum Genet.</source>
                <year>2010</year>
                <volume>128</volume>
                <fpage>79</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">20424861</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.wenstrup.2004">
              <mixed-citation publication-type="book">Wenstrup RJ, Hoechstetter LB. Ehlers-Danlos syndromes. In: Cassidy SB, Allanson JE, eds. <italic toggle="yes">Management of Genetic Syndromes</italic>. 2 ed. New York, NY: John Wiley &#x00026; Sons; 2004:211-24.</mixed-citation>
            </ref>
            <ref id="eds.REF.wenstrup.2004.53331">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wenstrup</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Florer</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunskill</surname>
                    <given-names>EW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bell</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chervoneva</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birk</surname>
                    <given-names>DE</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Type V collagen controls the initiation of collagen fibril assembly.</article-title>
                <source>J Biol Chem</source>
                <volume>279</volume>
                <fpage>53331</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15383546</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.wenstrup.2000.1766">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wenstrup</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Florer</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willing</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giunta</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Susic</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>WG</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>COL5A1 haploinsufficiency is a common molecular mechanism underlying the classical form of EDS.</article-title>
                <source>Am J Hum Genet</source>
                <volume>66</volume>
                <fpage>1766</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">10777716</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.wenstrup.2002.112">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wenstrup</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyle</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoechstetter</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rose</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francomano</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Prevalence of aortic root dilation in the Ehlers-Danlos syndrome.</article-title>
                <source>Genet Med</source>
                <volume>4</volume>
                <fpage>112</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12180144</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.zweers.2003.214">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zweers</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bristow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steijlen</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dean</surname>
                    <given-names>WB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamel</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otero</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kucharekova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boezeman</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schalkwijk</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome.</article-title>
                <source>Am J Hum Genet</source>
                <volume>73</volume>
                <fpage>214</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12865992</pub-id>
              </element-citation>
            </ref>
            <ref id="eds.REF.zweers.2005.330">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zweers</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dean</surname>
                    <given-names>WB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Kuppevelt</surname>
                    <given-names>TH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bristow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schalkwijk</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Elastic fiber abnormalities in hypermobility type Ehlers-Danlos syndrome patients with tenascin-X mutations.</article-title>
                <source>Clin Genet</source>
                <volume>67</volume>
                <fpage>330</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15733269</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="eds.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="eds.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>18 August 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>11 May 2010 (cd) Revision: changes in testing</p>
            </list-item>
            <list-item>
              <p>24 July 2008 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>29 May 2007 (cd) Revision: sequence analysis of entire coding region available for COL5A1 and COL5A2 and prenatal testing available</p>
            </list-item>
            <list-item>
              <p>10 April 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>29 October 2003 (ca) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>20 June 2003 (rw, ad) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="eds.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Skin hyperextensibility</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="eds-Image002" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="eds.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>Widened atrophic scars</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="eds-Image003" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="eds.F3" orientation="portrait">
          <label>Figure 3. </label>
          <caption>
            <p>Passive flexion of thumbs to the forearm: manifestation of joint hypermobility</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="eds-Image004" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
